Objective 

To evaluate the efficacy of the Defend 400 at reducing aerosolized MS2 bacteriophage virus, a surrogate for SARS-CoV-2, the virus causing COVID-19. 

Methodology 

MS2 bacteriophage was aerosolized into a 16 m³ sealed environmental bioaerosol chamber containing the Defend 400. 

AGI impingers were used to sample the chamber bioaerosol concentrations. All impinger samples were serially diluted, plated and enumerated in triplicate to yield viable bioaerosol concentration at each sampling point and time. Samples were taken at 0, 15, 30, 45 and 60 minutes in order to quantify the reduction speed and capabilities of the Defend 400. Chamber control trial data was subtracted from the Defend 400 trial data to yield net LOG reduction in the chamber for the bioaerosol challenges. 

This study was conducted in compliance with FDA Good Laboratory Practices (GLP) as defined in 21 CFR, Part 58. 

Summary of Results 

The Defend 400 achieved a net LOG reduction of MS2 bacteriophage virus after 45 minutes of 5.31 which is equivalent to a net percent reduction of 99.9995%.